Abstract: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.

Abstract: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.

Abstract: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.

Abstract: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.

Abstract: The invention relates to pharmaceutical compositions, as well as health functional food compositions and quasi-drug compositions, for preventing, treating, or improving rheumatoid arthritis, comprising a monoacetyldiacylglycerol compound as an active ingredient. The monoacetyldiacylglycerol of the invention is effective in inhibiting the phosphorylation of STAT-3 known to be a therapeutic target for rheumatoid arthritis. As the monoacetyldiacylglycerol is an effective therapeutic agent without toxicity, the monoacetyldiacylglycerol can overcome the side effects of the medicines currently used in the treatment of rheumatoid arthritis. Thus, the monoacetyldiacylglycerol can be used for preventing, treating or improving rheumatoid arthritis.

Abstract: The present invention relates to a pharmaceutical composition, functional health food composition, quasi-drug composition, and cosmetic composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing, treating or improving atopic dermatitis. The monoacetyldiacylglycerol compound of the present invention has an excellent effect of suppression of IL-4 and IgE secretion, thereby overcoming side effects of an atopic dermatitis treatment agent currently in use, having no toxicity, and exhibiting an excellent treatment effect, and thus can be useful as a composition for preventing, treating, and ameliorating atopic dermatitis.

Abstract: The present invention relates to compositions for promoting differentiation or proliferation of erythrocytic cells containing a monoacetyl diacylglycerol compound as an active ingredient, and pharmaceutical compositions and health functional food compositions for preventing, treating or alleviating erythrocytopenia containing the same. The monoacetyldiacylglycerol compound of the present invention is effective in promoting differentiation or proliferation of erythrocytic cells. The compound can overcome the side effects of the conventional anemia treatment medicines, and has less toxicity. Thus, the compound can be effectively used for preventing, treating or alleviating oligocythemia.

Abstract: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of atopy comprising the extract of Daphne genkwa, the fraction thereof, of the compound isolated from the same as an active ingredient. More precisely, the extract of Daphne genkwa, the fraction thereof, or the compound isolated from the same, genekwadapnin or yuanhuacine, of the present invention can increase the secretion of cytokine in Th1 immune cells and suppress atopy in the atopy mouse model, so that the extract of Daphne genkwa, the fraction thereof, or the compound isolated from the same of the present invention can be effectively used for the prevention or treatment of atopy.

Abstract: The invention relates to pharmaceutical compositions, as well as health functional food compositions and quasi-drug compositions, for preventing, treating, or improving rheumatoid arthritis, comprising a monoacetyldiacylglycerol compound as an active ingredient. The monoacetyldiacylglycerol of the invention is effective in inhibiting the phosphorylation of STAT-3 known to be a therapeutic target for rheumatoid arthritis. As the monoacetyldiacylglycerol is an effective therapeutic agent without toxicity, the monoacetyldiacylglycerol can overcome the side effects of the medicines currently used in the treatment of rheumatoid arthritis. Thus, the monoacetyldiacylglycerol can be used for preventing, treating or improving rheumatoid arthritis.

Abstract: The present invention relates to a pharmaceutical composition, functional health food composition, quasi-drug composition, and cosmetic composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing, treating or improving atopic dermatitis. The monoacetyldiacylglycerol compound of the present invention has an excellent effect of suppression of IL-4 and IgE secretion, thereby overcoming side effects of an atopic dermatitis treatment agent currently in use, having no toxicity, and exhibiting an excellent treatment effect, and thus can be useful as a composition for preventing, treating, and ameliorating atopic dermatitis.

Abstract: The present invention relates to an antiviral composition containing an Aleurites fordii or Daphne kiusiana extract or a fraction thereof as an active ingredient. In detail, extracts of Aleurites fordii or Daphne kiusiana or fractions thereof can induce the secretion of an immune-related cytokine, interferon-? (IFN-?) in natural killer (NK) cells, and thus exhibit potent antiviral activity and superior effects for viral diseases, and therefore can be effectively used in an antiviral composition.

Abstract: The invention relates to pharmaceutical compositions, as well as health functional food compositions and quasi-drug compositions, for preventing, treating, or improving rheumatoid arthritis, comprising a monoacetyldiacylglycerol compound as an active ingredient. The monoacetyldiacylglycerol of the invention is effective in inhibiting the phosphorylation of STAT-3 known to be a therapeutic target for rheumatoid arthritis. As the monoacetyldiacylglycerol is an effective therapeutic agent without toxicity, the monoacetyldiacylglycerol can overcome the side effects of the medicines currently used in the treatment of rheumatoid arthritis. Thus, the monoacetyldiacylglycerol can be used for preventing, treating or improving rheumatoid arthritis.

Abstract: The present invention relates to a diterpene compound derived from Aleurites fordii, and a pharmaceutical composition for treating or preventing viral infectious diseases, a health functional food for preventing or ameliorating viral infectious diseases and a composition for enhancing the production of interferon-gamma, which comprise the diterpene compound. Furthermore, the present invention relates to a method for preventing or treating viral infectious diseases including administering the composition to a subject having a viral infectious disease occurrence or a risk thereof with a therapeutically effective dose.

Abstract: The present invention relates to a pharmaceutical composition for treating wounds or revitalizing skin comprising the Euphorbia kansui extract, the fractions thereof, or the diterpene compound isolated therefrom as an active ingredient. The Euphorbia kansui extract may act on epithelial cells to induce PKD1 activity required for improving the reproduction capability of differentiated epithelial cells, and thus may induce the phosphorylation of lower ERK1 and the generation of Cycline D, thus exhibiting an excellent ability to activate the reproduction of damaged skin. Therefore, the Euphorbia kansui extract may be used effectively as an active ingredient in a pharmaceutical composition for treating wounds or reproducing skin, a health food for recovering skin damage or reproducing skin, or a functional cosmetic for inducing skin cell activity.

Abstract: The present invention relates to a pharmaceutical composition for treating wounds or revitalizing skin comprising the Euphorbia kansui extract, the fractions thereof, or the diterpene compound isolated therefrom as an active ingredient. The Euphorbia kansui extract may act on epithelial cells to induce PKD1 activity required for improving the reproduction capability of differentiated epithelial cells, and thus may induce the phosphorylation of lower ERK1 and the generation of Cycline D, thus exhibiting an excellent ability to activate the reproduction of damaged skin. Therefore, the Euphorbia kansui extract may be used effectively as an active ingredient in a pharmaceutical composition for treating wounds or reproducing skin, a health food for recovering skin damage or reproducing skin, or a functional cosmetic for inducing skin cell activity.

Abstract: The present invention relates to a diterpene compound derived from Aleurites fordii, and a pharmaceutical composition for treating or preventing viral infectious diseases, a health functional food for preventing or ameliorating viral infectious diseases and a composition for enhancing the production of interferon-gamma, which comprise the diterpene compound. Furthermore, the present invention relates to a method for preventing or treating viral infectious diseases including administering the composition to a subject having a viral infectious disease occurrence or a risk thereof with a therapeutically effective dose.

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of atopy comprising the extract of Daphne genkwa, the fraction thereof, of the compound isolated from the same as an active ingredient. More precisely, the extract of Daphne genkwa, the fraction thereof, or the compound isolated from the same, genekwadapnin or yuanhuacine, of the present invention can increase the secretion of cytokine in Th1 immune cells and suppress atopy in the atopy mouse model, so that the extract of Daphne genkwa, the fraction thereof, or the compound isolated from the same of the present invention can be effectively used for the prevention or treatment of atopy.

Abstract: The present invention relates to an antiviral composition containing an Aleurites fordii or Daphne kiusiana extract or a fraction thereof as an active ingredient. In detail, extracts of Aleurites fordii or Daphne kiusiana or fractions thereof can induce the secretion of an immune-related cytokine, interferon-? (IFN-?) in natural killer (NK) cells, and thus exhibit potent antiviral activity and superior effects for viral diseases, and therefore can be effectively used in an antiviral composition.